Overactive Bladder (OAB) is a common disorder whose symptoms include:
- urinary urgency
- urinary frequency
- urinary pain
While not life-threatening, OAB can greatly diminish a patient’s quality-of-life. Of the nearly 30 million Americans who suffer from OAB, most are treated orally with medications of dubious value. The large segment of this population has refractory OAB; their illness is unresponsive to oral medication. This unmet medical need represents a market worth between $400 million and $800 million per year. Other treatment options can be time-consuming, invasive, and painful. These include repeated injections of botulinum toxin directly into the bladder wall and various types of nerve stimulation. All require a cytoscopic procedure and may cause serious side effects.
LP-09 is a liposomal formulation of botulinum toxin. It has proven safe and effective for relieving symptoms of refractory OAB and can be administered in an outpatient procedure.
Hemorrhagic cystitis (HC) is an inflammatory illness marked by chronic bleeding in the bladder. It is a common side-effect radiation and chemotherapy used to treat cancers of the pelvic area—prostate, ovarian, cervical, bladder, and colorectal. Because the bladder exhibits slow cell-turnover, HC can emerge months or years after such procedures.
Unless managed sufficiently, advanced HC can require a cystectomy, the surgical removal of the bladder. In some cases, the condition is fatal. HC places a significant burden on patients and the healthcare system, and can be devastating to patients who are already fighting a malignancy.
Today, the most effective option for treating HC is hyperbaric oxygen (HBO) therapy. This process requires patients to sit in a pressurized room resembling an airline fuselage for long periods of time. HBO therapy is widely unavailable and expensive, ranging from $15k and $50k per treatment.
LP-10 (liposomal tacrolimus) has demonstrated proof-of-concept in animal models of both chemotherapy- and radiation-induced cystitis.